文献速递认知障碍与痴呆

记忆门诊患者早期与晚期淀粉样蛋白正电子发射断层成像的临床效果:AMYPAD-DPMS随机临床试验

Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

AMYPAD-DPMS是一项在8个欧洲记忆门诊开展的前瞻性随机临床试验,共纳入840例患者,按淀粉样蛋白PET在诊断流程中的时机分为早期组、晚期组和医生选择组。3个月后,早期组40%获得极高置信度的病因诊断,晚期组为11%(P < .001),各认知阶段结果一致。作者认为这些发现支持在记忆门诊患者诊断流程早期实施淀粉样蛋白PET。

要点

  • 早期淀粉样蛋白PET组3个月时40%获得极高置信度病因诊断,晚期组为11%(P < .001)。
  • 亚组分析显示主观认知下降伴附加特征、轻度认知障碍和痴呆阶段均一致(P < .001)。
  • 作者认为这些发现支持在记忆门诊患者诊断流程早期实施淀粉样蛋白PET。

核心结论

  • 在记忆门诊患者中,早期淀粉样蛋白PET使患者在仅3个月后即获得极高置信度的病因诊断,相比未进行淀粉样蛋白PET的患者。
  • 作者认为这些发现支持在记忆门诊患者诊断流程早期实施淀粉样蛋白PET。

研究设计与样本

  • AMYPAD-DPMS是一项在8个欧洲记忆门诊开展的前瞻性随机临床试验。
  • 采用最小化法将参与者分配到3个研究组:第1组在诊断流程早期(1个月内)行淀粉样蛋白PET;第2组在诊断流程晚期(平均[标准差]8[2]个月后)行淀粉样蛋白PET;第3组由主治医师决定是否及何时行淀粉样蛋白PET。
  • 参与者为伴有主观认知下降附加特征(SCD+;主观认知下降伴增加临床前阿尔茨海默病可能性的临床特征)、轻度认知障碍(MCI)或痴呆的患者,在基线和3个月后评估。
  • 共筛选844例,纳入840例(第1组291例,第2组271例,第3组278例);第1组272例和第2组260例有基线和3个月访视数据。
  • 招募时间为2018年4月16日至2020年10月30日;数据分析时间为2022年7月至2023年1月。

主要发现

  • 3个月后,第1组272例中109例(40%)获得极高置信度诊断,第2组260例中30例(11%)获得极高置信度诊断(P < .001)。
  • 主观认知下降附加特征亚组:第1组25/84(30%)vs 第2组5/78(6%)(P < .001)。
  • 轻度认知障碍亚组:第1组45/108(42%)vs 第2组9/102(9%)(P < .001)。
  • 痴呆亚组:第1组39/80(49%)vs 第2组16/80(20%)(P < .001)。

关键数值与推荐

  • 主要结局为3个月后第1组与第2组获得极高置信度病因诊断(即在50%-100%视觉数字量表上≥90%)的参与者比例差异。
  • 第1组272例中109例(40%)vs 第2组260例中30例(11%)(P < .001)。
  • 主观认知下降附加特征:第1组25/84(30%)vs 第2组5/78(6%)(P < .001)。
  • 轻度认知障碍:第1组45/108(42%)vs 第2组9/102(9%)(P < .001)。
  • 痴呆:第1组39/80(49%)vs 第2组16/80(20%)(P < .001)。

临床怎么用

  • 作者认为这些发现支持在记忆门诊患者诊断流程早期实施淀粉样蛋白PET。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect. OBJECTIVE: To assess the clinical effect of amyloid PET in memory clinic patients. DESIGN, SETTING, AND PARTICIPANTS: The AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics. Participants were allocated (using a minimization method) to 3 study groups based on the performance of amyloid PET: arm 1, early in the diagnostic workup (within 1 month); arm 2, late in the diagnostic workup (after a mean [SD] 8 [2] months); or arm 3, if and when the managing physician chose. Participants were patients with subjective cognitive decline plus (SCD+; SCD plus clinical features increasing the likelihood of preclinical Alzheimer disease), mild cognitive impairment (MCI), or dementia; they were assessed at baseline and after 3 months. Recruitment took place between April 16, 2018, and October 30, 2020. Data analysis was performed from July 2022 to January 2023. INTERVENTION: Amyloid PET. MAIN OUTCOME AND MEASURE: The main outcome was the difference between arm 1 and arm 2 in the proportion of participants receiving an etiological diagnosis with a very high confidence (ie, ≥90% on a 50%-100% visual numeric scale) after 3 months. RESULTS: A total of 844 participants were screened, and 840 were enrolled (291 in arm 1, 271 in arm 2, 278 in arm 3). Baseline and 3-month visit data were available for 272 participants in arm 1 and 260 in arm 2 (median [IQR] age: 71 [65-77] and 71 [65-77] years; 150/272 male [55%] and 135/260 male [52%]; 122/272 female [45%] and 125/260 female [48%]; median [IQR] education: 12 [10-15] and 13 [10-16] years, respectively). After 3 months, 109 of 272 participants (40%) in arm 1 had a diagnosis with very high confidence vs 30 of 260 (11%) in arm 2 (P < .001). This was consistent across cognitive stages (SCD+: 25/84 [30%] vs 5/78 [6%]; P < .001; MCI: 45/108 [42%] vs 9/102 [9%]; P < .001; dementia: 39/80 [49%] vs 16/80 [20%]; P < .001). CONCLUSION AND RELEVANCE: In this study, early amyloid PET allowed memory clinic patients to receive an etiological diagnosis with very high confidence after only 3 months compared with patients who had not undergone amyloid PET. These findings support the implementation of amyloid PET early in the diagnostic workup of memory clinic patients. TRIAL REGISTRATION: EudraCT Number: 2017-002527-21.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Altomare D, Barkhof F, Caprioglio C, et al. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37155177. doi:10.1001/jamaneurol.2023.0997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。